ACLA Statement on COVID-19 Vaccine Approval
Washington, D.C. – Following the Food and Drug Administration’s (FDA) emergency use authorization (EUA) of a COVID-19 vaccine, ACLA President Julie Khani issued the following statement:
“With the FDA’s first EUA of a COVID-19 vaccine, the country is pushing forward in delivering a modern-day miracle to the public. The sheer scientific and medical advancement of this moment is one that should be commended for years to come, and ACLA and its members applaud all of the researchers, scientists and public health experts involved in making a safe and effective vaccine available.
As vaccinations occur consistent with Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations, COVID-19 testing remains a critical component of our response to this deadly virus. Clinical labs are doing everything possible to ensure that COVID-19 testing remains accessible so that we can continue to halt and contain the spread of the virus in our communities. We remain committed to supporting our nationwide public health goals in response to COVID-19 and providing the testing that the country needs to move forward from this public health crisis.”
The American Clinical Laboratory Association (ACLA) is the national trade association representing leading laboratories that deliver essential diagnostic health information to patients and providers. ACLA members are at the forefront of driving diagnostic innovation to meet the country’s evolving health care needs and provide vital clinical laboratory tests that identify and prevent infectious, acute and chronic disease. ACLA works to advance the next generation of health care delivery through policies that expand access to lifesaving testing services